Impax Asset Management Group
CYTK icon

Impax Asset Management Group’s Cytokinetics CYTK Stock Holding History

Impax Asset Management Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Buy
165,000
+40,000
+32% +$2.87M 0.09% 145
2026
Q1 		$8.24M Buy
125,000
+25,000
+25% +$1.59M 0.06% 171
2025
Q4 		$6.35M Sell
100,000
-75,000
-43% -$4.67M 0.04% 192
2025
Q3 		$9.62M Hold
175,000
– – 0.06% 145
2025
Q2 		$5.78M Hold
175,000
– – 0.03% 196
2025
Q1 		$7.03M Hold
175,000
– – 0.04% 171
2024
Q4 		$8.23M Buy
175,000
+50,000
+40% +$2.6M 0.04% 177
2024
Q3 		$6.6M Hold
125,000
– – 0.03% 203
2024
Q2 		$6.77M Buy
+125,000
New +$7.55M 0.03% 199

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impax Asset Management Group's CYTK Position: Q2 2026 in Review

Impax Asset Management Group increased its Cytokinetics (CYTK) stake by 32% in Q2 2026, buying an estimated $2.87M and bringing the position to 165,000 shares worth $14.1M. The position accounts for 0.09% of the portfolio, ranked #145.

Impax Asset Management Group first reported a position in CYTK in Q2 2024 and has held it in 9 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Impax Asset Management Group held 165,000 shares of Cytokinetics worth $14.1M as of Q2 2026.
  • Impax Asset Management Group bought 40,000 Cytokinetics shares in Q2 2026, an estimated $2.87M.
  • Cytokinetics made up 0.09% of Impax Asset Management Group's portfolio in Q2 2026, its #145 holding.
  • Impax Asset Management Group first reported a position in Cytokinetics in Q2 2024 and has held it in 9 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.